Literature DB >> 15270723

Increased expression of the natural killer cell inhibitory receptor CD85j/ILT2 on antigen-specific effector CD8 T cells and its impact on CD8 T-cell function.

M Nedim Ince1, Brooke Harnisch, Zhan Xu, Sang-Kyung Lee, Christoph Lange, Lorenzo Moretta, Michael Lederman, Judy Lieberman.   

Abstract

We investigated whether inhibitory natural killer cell receptor (iNKR) expression contributes to impaired antigen-specific cytotoxicity and interferon-gamma (IFN-gamma) production by CD8 T cells during chronic infection. iNKR immunoglobulin-like transcript-2 (ILT2/CD85j) is expressed on 40-55% of cytomegalovirus (CMV)-, Epstein-Barr virus (EBV)- and human immunodeficiency virus (HIV)-specific CD8 T cells in both healthy and HIV-infected donors. Other iNKRs (CD158a, b1, e1/e2, k, CD94/NKG2A) are expressed on only a small minority of CD8 T cells and are not preferentially expressed on tetramer-staining virus-specific cells. In normal donors, ILT2 is expressed largely on perforin(+) CD27(-) effector cells. However, in HIV-infected donors, only a third of ILT2(+) cells are also perforin(+). In both normal and HIV-infected donors, ILT2(+) cells are prone to spontaneous apoptosis. Therefore, ILT2 is normally expressed during effector cytotoxic T-lymphocyte (CTL) differentiation, but can also be expressed when effector maturation is incomplete, as in HIV infection. The effect of ILT2 on CD8 cell function was assessed by preincubating effector cells with ILT2 antibody. While blocking ILT2 engagement has no appreciable effect on cytotoxicity, it increases antiviral IFN-gamma production by approximately threefold in both normal and HIV-infected donors. Thus, ILT2 expression, increased on antiviral CD8 cells in chronic infection, may interfere with protective CD8 T-cell function by suppressing IFN-gamma production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15270723      PMCID: PMC1782522          DOI: 10.1046/j.1365-2567.2004.01907.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  58 in total

1.  The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells.

Authors:  G B Cohen; R T Gandhi; D M Davis; O Mandelboim; B K Chen; J L Strominger; D Baltimore
Journal:  Immunity       Date:  1999-06       Impact factor: 31.745

2.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

3.  Differential regulation of killer cell Ig-like receptors and CD94 lectin-like dimers on NK and T lymphocytes from HIV-1-infected individuals.

Authors:  P André; C Brunet; S Guia; H Gallais; J Sampol; E Vivier; F Dignat-George
Journal:  Eur J Immunol       Date:  1999-04       Impact factor: 5.532

4.  Viral clearance without destruction of infected cells during acute HBV infection.

Authors:  L G Guidotti; R Rochford; J Chung; M Shapiro; R Purcell; F V Chisari
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

5.  The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells.

Authors:  F Navarro; M Llano; T Bellón; M Colonna; D E Geraghty; M López-Botet
Journal:  Eur J Immunol       Date:  1999-01       Impact factor: 5.532

6.  CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients.

Authors:  D E Speiser; D Valmori; D Rimoldi; M J Pittet; D Liénard; V Cerundolo; H R MacDonald; J C Cerottini; P Romero
Journal:  Eur J Immunol       Date:  1999-06       Impact factor: 5.532

7.  Expression of killer inhibitory receptors on cytotoxic cells from HIV-1-infected individuals.

Authors:  M D Galiani; E Aguado; R Tarazona; P Romero; I Molina; M Santamaria; R Solana; J Peña
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

8.  Selective induction of CD8+ cytotoxic T lymphocyte effector function by staphylococcus enterotoxin B.

Authors:  C L Fuller; V L Braciale
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

9.  Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).

Authors:  C M Gray; J Lawrence; J M Schapiro; J D Altman; M A Winters; M Crompton; M Loi; S K Kundu; M M Davis; T C Merigan
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

10.  Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic.

Authors:  Dong Zhang; Premlata Shankar; Zhan Xu; Brooke Harnisch; Gang Chen; Christoph Lange; Sandra J Lee; Hernan Valdez; Michael M Lederman; Judy Lieberman
Journal:  Blood       Date:  2002-08-22       Impact factor: 22.113

View more
  24 in total

1.  Finding Balance: T cell Regulatory Receptor Expression during Aging.

Authors:  Mary M Cavanagh; Qian Qi; Cornelia M Weyand; Jörg J Goronzy
Journal:  Aging Dis       Date:  2011-10-28       Impact factor: 6.745

2.  Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin-like receptors.

Authors:  Gabriella Henel; Karnail Singh; Dapeng Cui; Sergey Pryshchep; Won-Woo Lee; Cornelia M Weyand; Jörg J Goronzy
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

3.  Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia.

Authors:  Mónica Villa-Álvarez; Seila Lorenzo-Herrero; Ana P Gonzalez-Rodriguez; Alejandro López-Soto; Angel R Payer; Esther Gonzalez-Garcia; Leticia Huergo-Zapico; Segundo Gonzalez
Journal:  Oncoimmunology       Date:  2017-07-20       Impact factor: 8.110

4.  Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer.

Authors:  Emilie Lesport; Jeremy Baudhuin; Sylvie Sousa; Joel LeMaoult; Alessia Zamborlini; Nathalie Rouas-Freiss; Edgardo D Carosella; Benoit Favier
Journal:  Cell Mol Life Sci       Date:  2011-02-20       Impact factor: 9.261

5.  LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8+ T Cells.

Authors:  Aeryon Kim; Chia-Jung Han; Ian Driver; Aleksandra Olow; Andrew K Sewell; Zemin Zhang; Wenjun Ouyang; Jackson G Egen; Xin Yu
Journal:  J Immunol       Date:  2019-06-28       Impact factor: 5.422

6.  Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers.

Authors:  Jinghe Huang; Patrick S Burke; Thai Duong Hong Cung; Florencia Pereyra; Ildiko Toth; Bruce D Walker; Luis Borges; Mathias Lichterfeld; Xu G Yu
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

7.  Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence.

Authors:  María Cecilia Albareda; Gabriela Carina Olivera; Susana A Laucella; María Gabriela Alvarez; Esteban Rodrigo Fernandez; Bruno Lococo; Rodolfo Viotti; Rick L Tarleton; Miriam Postan
Journal:  J Immunol       Date:  2009-08-19       Impact factor: 5.422

Review 8.  Regulation of T-cell immunity by leucocyte immunoglobulin-like receptors: innate immune receptors for self on antigen-presenting cells.

Authors:  Katie J Anderson; Rachel L Allen
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

9.  Human papillomavirus immunization is associated with increased expression of different innate immune regulatory receptors.

Authors:  V Colmenares; D E Noyola; A Monsiváis-Urenda; M Salgado-Bustamante; L Estrada-Capetillo; R González-Amaro; L Baranda
Journal:  Clin Vaccine Immunol       Date:  2012-05-09

10.  Effect of ageing on CMV-specific CD8 T cells from CMV seropositive healthy donors.

Authors:  María Luisa Pita-Lopez; Inmaculada Gayoso; Olga DelaRosa; Javier G Casado; Corona Alonso; Elisa Muñoz-Gomariz; Raquel Tarazona; Rafael Solana
Journal:  Immun Ageing       Date:  2009-08-28       Impact factor: 6.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.